Tandem Diabetes Care, Inc.
TNDMTandem Diabetes Care, Inc. is a medical device company that develops and commercializes products for the management of insulin-dependent diabetes. Founded in 2008 and headquartered in California, the company is known for its innovative insulin pump systems, including the t:slim X2 insulin pump, designed to improve diabetes treatment through advanced technology and user-friendly features. Tandem aims to empower people with diabetes to achieve better health outcomes through integrated and automated insulin delivery solutions.
Company News
The FDA has classified a Class I recall for Tandem Diabetes Care's Mobi insulin pumps due to a potential 'false motor failure' detection that could halt insulin delivery. Affected devices running software versions 7.6.0.1, 7.6.0.3, and 7.7.0.1 must be updated to version 7.9.0.2. As of November 4, 2025, four serious injuries have been reported wit...
The Portnoy Law Firm has initiated a securities fraud investigation into Tandem Diabetes Care following a 19.9% stock price decline on August 7, 2025. The drop was triggered by the company's disclosure of a malfunction in its insulin pumps that could discontinue insulin delivery and cause hyperglycemia. Tandem had notified affected customers befo...
The global intravenous infusion pump market was valued at USD 6.72 billion in 2025 and is projected to reach USD 14.02 billion by 2035, growing at a CAGR of 7.6%. Growth is driven by increasing chronic diseases, aging populations, technological advancements in smart pumps, and rising demand for precise medication delivery in hospitals and home ca...
Tandem Diabetes Care (NASDAQ: TNDM) shares surged 33-37% following strong Q4 earnings results that beat expectations with adjusted loss of $0.01 vs. consensus loss of $0.08, and sales of $290.4M exceeding the $277M consensus. The company reported significant margin expansion with adjusted gross profit jumping from 51% to 58%, and adjusted operati...
The Rosen Law Firm is investigating potential securities claims on behalf of Tandem Diabetes Care shareholders following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the news. The...
